Lymphoma is a group of malignant neoplasms of lymphocytes that progress in the lymphatic system. Generally, lymphomas are categorized into two groups: non-Hodgkin lymphoma and Hodgkin lymphoma. Depending on which type of lymphocyte is affected, NHL is classified into B-cell and T-cell NHL. The treatment landscape of B-cell NHL has evolved with the recent treatment developments, including chimeric antigen receptor (CAR) T-cell therapies. Axicabtagene ciloleucel (axi-cel), a CAR T-cell product, is currently being evaluated in patients with follicular lymphoma or marginal zone lymphoma in the ZUMA-5 trial. Additionally, lisocabtagene maraleucel (liso-cel) demonstrated promising clinical activity among patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), according to the TRANSCEND study. One of the novel CAR T-cell products, AUTO3, which contains two independent CARs targeting CD19 and CD22, is being evaluated in patients with R/R diffuse large B-cell lymphoma.
In this fascinating podcast, Sattva Neelapu, MD, University of Texas MD Anderson Cancer Center, Houston, TX, Michael Wang, MD, University of Texas MD Anderson Cancer Center, Houston, TX, and Aravind Ramakrishnan, MD, Sarah Cannon Blood Cancer Center at St. David’s South Austin Medical Center, Austin, TX, discuss CAR T-cell therapy updates in the lymphoma field presented at the 62nd American Society of Hematology (ASH) 2020 Annual Meeting and Exposition.
The post Advances in CAR T-cell therapies for lymphoma from ASH 2020 appeared first on VJHemOnc.
